Viridian Therapeutics adds exec to board
BOULDER — Biotech company Viridian Therapeutics (NYSE: VRDN) has appointed Jennifer K. Moses to its board of directors, according to documents filed Thursday with the Securities and Exchange Commission.
Moses is currently the chief financial officer for GI Therapeutics Inc. (NYSE: GTHX), a commercial-stage oncology company. She has also served as a partner at Rankin McKenzie LLC and Deloitte.
Moses will be compensated with an annual cash retainer of $55,000 and the option to purchase 25,000 shares of Viridian stock.
SPONSORED CONTENT
Exploring & expressing grief
Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.
© 2021 BizWest Media LLC
BOULDER — Biotech company Viridian Therapeutics (NYSE: VRDN) has appointed Jennifer K. Moses to its board of directors, according to documents filed Thursday with the Securities and Exchange Commission.
Moses is currently the chief financial officer for GI Therapeutics Inc. (NYSE: GTHX), a commercial-stage oncology company. She has also served as a partner at Rankin McKenzie LLC and Deloitte.
Moses will be compensated with an annual cash retainer of $55,000 and the option to purchase 25,000 shares of Viridian stock.
© 2021 BizWest Media LLC
…THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
